Angiogenesis in Dermatology - Insights of Molecular Mechanisms and Latest Developments.
Angiogenesis is the growth of new blood vessels from pre-existing vessels. It is a biological process essential in physiological wound healing or pathological inflammation and tumor growth, which underlies a complex interplay of stimulating and inhibiting signals. Extracellular matrix, cells of innate and adaptive immunity and endothelial cells itself are a major source of angiogenic factors that activate or inhibit specific receptors and consequently influence intracellular signaling pathways. Most inflammatory and neoplastic diseases in dermatology are characterized by excessive angiogenesis, such as psoriasis, atopic dermatitis, as well as melanoma, non-melanoma skin cancer, but also benign vascular neoplasia. In this article we describe current knowledge of angiogenesis and its most relevant mechanisms in different dermatological disorders with particular emphasis on the angiogenic factors (vascular endothelial growth factor) and angiopoietins as a target of current and future directions of anti-angiogenic therapy.
Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Electronic address: richarznina@gmail.com.
N A
NA
Richarz
Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
A
A
Boada
Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
J M
JM
Carrascosa
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D042501:Angiogenic Proteins / Q000502:physiology; D042682:Angiopoietins / Q000037:antagonists & inhibitors / Q000502:physiology; D019008:Drug Resistance, Neoplasm; D006391:Hemangioma / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008545:Melanoma / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D018919:Neovascularization, Physiologic; D011565:Psoriasis / Q000188:drug therapy / Q000503:physiopathology; D042787:Receptor, TIE-2 / Q000037:antagonists & inhibitors / Q000502:physiology; D012867:Skin / Q000098:blood supply; D012871:Skin Diseases / Q000150:complications* / Q000276:immunology / Q000503:physiopathology; D012878:Skin Neoplasms / Q000098:blood supply / Q000150:complications / Q000276:immunology / Q000503:physiopathology
D020533:Angiogenesis Inhibitors; D042501:Angiogenic Proteins; D042682:Angiopoietins; D009363:Neoplasm Proteins; D042787:Receptor, TIE-2
Angiopoietin; Angiopoietina; Antiangiogenic therapy; Factor de crecimiento vascular endotelial; Melanoma; Psoriasis; Terapia antiangiogénica; Vascular endothelial growth factor